DAPAGLIFLOZIN TREATMENT IMPROVE RENAL FUNCTION PARAMETERS AND TUBULE-INTERSTITIAL INJURY IN SUBCLINICAL ACUTE KIDNEY INJURY

Subclinical acute kidney injury (subAKI) is a syndrome characterized by markers of tubular injury without changes in glomerular function. Due to its silent feature, subAKI is a risk factor for AKI and chronic kidney disease (CKD) development. Currently, the treatment of subAKI is still limited. Recently, the use of SGLT2 inhibitors has shown improved kidney function parameters in patients with CKD and other mouse models of kidney diseases. These effects are associated with reduced kidney inflammation and fibrosis. In addition, mTOR inhibitors has also shown beneficial effects on kidney function parameters, since this signaling pathway is overactivated in different types of kidney diseases. However, the effects of dapagliflozin, a SGLT2 inhibitor, and rapamycin, a mTORC1 inhibitor, on the development of tubule-interstitial injury observed in subAKI is still unknown.